Thematic evaluation
Back to company overview

Danaher Corp. (DHR)

September 06, 2024

Compared to: Thermo Fisher Scientific, Inc. (TMO) | Agilent Technologies, Inc. (A) | Health Care Select Sector SPDR Fund (XLV)

Our reasoning

Danaher Corp. appears slightly undervalued based on its strong competitive position, robust R&D pipeline, and financial performance metrics that outperform industry averages. While facing challenges such as declining COVID-19 related demand, the company's diversified portfolio and focus on high-growth markets provide resilience. The current P/E ratio below historical and industry averages, combined with strong profitability metrics, suggests the market may not fully appreciate the company's long-term growth potential.

Key takeaways
  • Danaher Corp. (DHR) is a diversified science and technology leader with a strong track record of growth and profitability, but faces challenges from a slowdown in certain end markets, intense competition, and regulatory headwinds.
  • DHR's aggressive M&A strategy and share repurchase program have reduced its cash balances, though the company maintains a strong liquidity position to fund future growth.
  • DHR's valuation is in line with its peers, suggesting that the company is fairly valued, but its recent underperformance and potential decline in profitability could put downward pressure on its valuation.
  • DHR's future performance will depend on its ability to navigate a number of challenges, including a slowdown in certain end markets, intense competition, and regulatory headwinds.
  • DHR's strong cash flow generation, robust R&D pipeline, and strategic focus on high-growth markets provide a foundation for future growth.
  • DHR's management expects a core revenue decline in the low single-digit percent range for the full year 2024, with a full-year adjusted operating profit margin of approximately 29%.
  • Analyst estimates are generally in line with management guidance, suggesting a consensus view of a modest decline in revenue and a stable profit margin.
  • DHR's overall investment characteristics are characterized by a strong competitive position in its target markets, a focus on innovation and shareholder returns, and a track record of successful strategic execution.
Undervalued
Ask a question about Danaher Corp. (DHR)
Evaluation summary

  1. Company Overview:

    • Danaher Corp. (DHR) is a global science and technology leader operating in the biotechnology, life sciences, diagnostics, and environmental and applied solutions sectors. The company's business model is built on a combination of organic growth and strategic acquisitions, with a focus on high-growth markets.
    • DHR's product and service portfolio includes a wide range of equipment, consumables, software, and services used in research, drug development, manufacturing, and medical diagnostics. The company's revenue is generated from a diverse customer base, including pharmaceutical/biotech companies, academic/research institutions, and healthcare providers.
    • DHR operates in over 50 countries, with a significant presence in North America, Europe, and Asia. The company's target markets are characterized by strong growth potential, driven by factors such as increasing healthcare spending, technological advancements, and a growing global population.
    • For comparative analysis, we will be using the Health Care Select Sector SPDR Fund (XLV) as a benchmark and Agilent Technologies, Inc. (A) and Thermo Fisher Scientific, Inc. (TMO) as industry peers.

  2. Financial Performance:

    • DHR has experienced a decline in revenue in recent quarters, primarily due to lower demand for COVID-19 related products and services. However, the company has effectively controlled operating expenses, mitigating the impact of declining revenue on profitability.
    • DHR's profitability remains strong, with return on average assets (ROA), return on average total equity (ROE), and return on average total capital (ROIC) all above the industry average. However, these profitability ratios are decreasing, suggesting a potential decline in future profitability.
    • Compared to its peers, DHR's profitability metrics are mixed. While DHR has outperformed its peers in some periods, it has underperformed in others, suggesting that its profitability is not consistently superior to its peers.

  3. Operational Efficiency:

    • DHR's balance sheet reflects its aggressive M&A strategy and share repurchase program, with a significant amount of intangible assets and a decreasing level of total equity.
    • The company's working capital management is efficient, with a strong current ratio and quick ratio. However, these liquidity ratios are decreasing, suggesting a potential decline in future liquidity.
    • DHR's cash flow generation capability is strong, with positive operating cash flow trends and a cash flow to net income ratio above 1. The company's free cash flow is expected to remain strong, providing it with the flexibility to continue its share repurchase program and invest in organic growth opportunities.
    • DHR's capital expenditure analysis reveals a trend of increasing fixed assets, indicating a focus on expanding its operational capacity. The company's dividend and share repurchase program is sustainable, supported by its strong cash flow generation.
    • Compared to its peers, DHR's operational efficiency is mixed. While DHR's lower volatility and maximum drawdown suggest a lower risk profile, its lower annualized returns and Sharpe Ratio indicate that it may not be offering as good a risk-adjusted return as its peers.

  4. Growth Opportunities:

    • DHR's growth opportunities are driven by its focus on high-growth markets, including biotechnology, life sciences, and diagnostics. The company is expanding its market reach through strategic acquisitions, such as the acquisition of Abcam plc, a leading supplier of protein research tools.
    • DHR's R&D pipeline is robust, with a focus on developing innovative products and services that address unmet needs in its target markets. The company is also expanding its geographic reach, with a particular focus on emerging markets with high growth potential.
    • DHR's strategic focus areas include innovation, sustainability, and shareholder returns. The company is committed to investing in R&D, developing sustainable business practices, and returning value to shareholders through share repurchases and dividends.
    • DHR's management has a track record of successfully executing strategic plans, as evidenced by the company's consistent growth and profitability.

  5. Risks and Threats:

    • DHR faces intense competition in its target markets, with a range of companies from large diversified conglomerates to specialized competitors. The company must continually innovate to maintain its market position and navigate complex regulatory environments.
    • DHR's aggressive M&A strategy and share repurchase program have reduced its cash balances, though the company maintains a strong liquidity position to fund future growth. The company's decrease in total equity is a potential red flag, as it could indicate a reduction in its financial flexibility.
    • DHR's operations are subject to a range of risks, including global economic conditions, healthcare industry dynamics, cybersecurity threats, and regulatory compliance. The company must effectively manage these risks to ensure its continued success.

  6. Valuation Analysis:

    • DHR's valuation metrics, such as P/E and EV/EBITDA, are in line with its peers, suggesting that the company is fairly valued. However, the company's recent underperformance and potential decline in profitability could put downward pressure on its valuation.
    • Compared to its peers, DHR's valuation is mixed. While DHR's lower volatility and maximum drawdown suggest a lower risk profile, its lower annualized returns and Sharpe Ratio indicate that it may not be offering as good a risk-adjusted return as its peers.

  7. Price Performance:

    • DHR's price performance has been mixed compared to its benchmark, XLV. While DHR has outperformed XLV in some periods, it has underperformed in others, suggesting that its price performance is not consistently superior to its benchmark.
    • DHR's price has been more volatile than XLV's price, as evidenced by its higher annualized volatility. This indicates that DHR's price is more susceptible to fluctuations than XLV's price.
    • Compared to its peers, DHR's price performance is mixed. While DHR has outperformed its peers in some periods, it has underperformed in others, suggesting that its price performance is not consistently superior to its peers.

  8. Future Outlook:

    • DHR's future outlook is uncertain, with the company facing a number of challenges, including a slowdown in certain end markets, intense competition, and regulatory headwinds. However, the company's strong cash flow generation, robust R&D pipeline, and strategic focus on high-growth markets provide a foundation for future growth.
    • DHR's management expects a core revenue decline in the low single-digit percent range for the full year 2024, with a full-year adjusted operating profit margin of approximately 29%. Analyst estimates are generally in line with management guidance, suggesting a consensus view of a modest decline in revenue and a stable profit margin.

  9. Summary:

    • DHR is a diversified science and technology leader with a strong track record of growth and profitability. The company's focus on high-growth markets, robust R&D pipeline, and efficient operations provide a foundation for future growth.
    • However, DHR faces a number of challenges, including a slowdown in certain end markets, intense competition, and regulatory headwinds. The company's aggressive M&A strategy and share repurchase program have reduced its cash balances, though the company maintains a strong liquidity position to fund future growth.
    • DHR's valuation is in line with its peers, suggesting that the company is fairly valued. However, the company's recent underperformance and potential decline in profitability could put downward pressure on its valuation.
    • Overall, DHR is a well-managed company with a strong competitive position in its target markets. However, the company's future performance will depend on its ability to navigate a number of challenges, including a slowdown in certain end markets, intense competition, and regulatory headwinds.
Peer fundamentals 
Fundamentals
Insights
  • Danaher is a diversified science and technology leader focused on high-growth life sciences and diagnostics markets, with a track record of strategic acquisitions to expand its capabilities.
  • The company faces intense competition and must continually innovate to maintain its market position, while also navigating complex regulatory environments and economic headwinds.
  • After strong performance during the COVID-19 pandemic, Danaher has seen a decline in demand for its pandemic-related products, putting pressure on its core sales and profitability.
  • Danaher's aggressive M&A strategy and share repurchase program have reduced its cash balances, though the company maintains a strong liquidity position to fund future growth.
  • Key risks include competition, technological change, healthcare industry dynamics, global economic conditions, cybersecurity threats, and regulatory compliance - managing these risks will be critical to Danaher's continued success.
  • The company's financial flexibility is expected to remain strong, as it has a significant amount of cash on hand and a low level of debt.
  • The company expects a core revenue decline in the low single-digit percent range for the full year 2024.
  • The company expects a full-year adjusted operating profit margin of approximately 29%.
  • The company's overall capital allocation strategy is shifting towards shareholder returns, as evidenced by the increased share repurchases.
  • The company's future cash flows are expected to be impacted by the continued slowdown in certain end markets.
  • The company's balance sheet is expected to continue to reflect its aggressive M&A strategy and share repurchase program.
  • The company's announced strategic initiatives, such as the acquisition of Abcam plc, are expected to have a positive impact on future cash flows.
Analysis
  • Revenue - Revenue is decreasing, primarily due to lower demand for COVID-19 related products and services. - The company expects a core revenue decline in the low single-digit percent range for the full year 2024. - The company is effectively controlling operating expenses, which is helping to mitigate the impact of declining revenue.
    • Profitability
      • Profitability is declining, as margins are being squeezed by lower sales volumes and product mix changes.
      • The company's return on average assets, return on average total equity, and return on average total capital are all above the industry average, indicating strong profitability relative to its peers.
      • However, these profitability ratios are decreasing, suggesting a potential decline in future profitability.
    • Liquidity
      • The company's liquidity position is strong, as evidenced by the current ratio and quick ratio, which are both above 1.
      • However, these liquidity ratios are decreasing, suggesting a potential decline in future liquidity.
    • Solvency
      • The company's financial leverage is low, as evidenced by the total debt to total equity ratio, which is below the industry average.
      • The company's debt to EBITDA ratio is also below the industry average, indicating a strong ability to service its debt.
      • However, the company's debt to EBITDA ratio is increasing, suggesting a potential increase in financial leverage in the future.
    • Operational Efficiency
      • The company's asset utilization efficiency is improving, as evidenced by the decreasing inventory levels and the increasing fixed assets.
      • The company's free cash flow margin is increasing, indicating improved cash flow generation efficiency.
    • Cash Flow Analysis
      • The company's cash flow generation capability is strong, as evidenced by the positive operating cash flow trends and the cash flow to net income ratio above 1.
      • The company's free cash flow is expected to remain strong, providing it with the flexibility to continue its share repurchase program and invest in organic growth opportunities.
      • The company's overall capital allocation strategy is shifting towards shareholder returns, as evidenced by the increased share repurchases.
    • Risk Factors
      • The company faces intense competition and must continually innovate to maintain its market position, while also navigating complex regulatory environments and economic headwinds.
      • The company's aggressive M&A strategy and share repurchase program have reduced its cash balances, though the company maintains a strong liquidity position to fund future growth.
      • The decrease in total equity is a potential red flag, as it could indicate a reduction in the company's financial flexibility.
    • Future Outlook
      • The company's future cash flows are expected to be impacted by the continued slowdown in certain end markets.
      • The company's balance sheet is expected to continue to reflect its aggressive M&A strategy and share repurchase program.
      • The company's financial flexibility is expected to remain strong, as it has a significant amount of cash on hand and a low level of debt.
      • The company expects a core revenue decline in the low single-digit percent range for the full year 2024.
      • The company expects a full-year adjusted operating profit margin of approximately 29%.
Most recent earnings report
Financial statements 
All public filings
Comparative Analysis
Benchmarks (as of 2024-09-04)
Health Care Select Sector SPDR Fund (XLV)
  • Performance Comparison:
    • DHR has consistently underperformed XLV over all the periods analyzed. This underperformance is particularly pronounced over longer periods, with DHR underperforming XLV by 29.08% over the past three years.
    • DHR's performance has been less consistent than XLV's, with larger fluctuations in its returns. This suggests that DHR's price is more susceptible to market volatility.
  • Risk and Return Analysis:
    • DHR has provided lower annualized returns than XLV over all the periods analyzed. This suggests that DHR has not been as profitable as XLV.
    • DHR has been more volatile than XLV, as evidenced by its higher annualized volatility. This indicates that DHR's price is more susceptible to fluctuations than XLV's price.
    • DHR has experienced significantly larger maximum drawdowns than XLV. This suggests that DHR is a riskier investment than XLV, as its price is more prone to sharp declines.
  • Risk-Adjusted Performance:
    • XLV has consistently offered a better risk-adjusted return than DHR, as indicated by its higher Sharpe ratio. This suggests that XLV has been more efficient at generating returns relative to its risk.
    • DHR's higher beta suggests that it is more sensitive to market movements than XLV. This means that DHR's price is likely to fluctuate more than XLV's price in response to market movements.
  • Overall Assessment:
    • DHR has underperformed XLV in terms of both absolute and risk-adjusted returns. DHR has also been more volatile and has experienced larger drawdowns than XLV. This suggests that DHR is a riskier investment than XLV.
    • The analysis suggests that XLV may be a more attractive investment option for investors seeking a more stable and less volatile investment. However, it is important to note that past performance is not necessarily indicative of future results.
Peers Price History(as of 2024-09-04)
Thermo Fisher Scientific, Inc. (TMO)Agilent Technologies, Inc. (A)
  • Performance Comparison: Danaher Corp. (DHR) has exhibited a mixed performance history compared to its peers, Agilent Technologies, Inc. (A) and Thermo Fisher Scientific, Inc. (TMO). While DHR has outperformed its peers in some periods, such as the 6-month and 3-year periods, it has underperformed in others, like the 1-month and 3-month periods. This suggests that DHR's performance is not consistently superior to its peers.
  • Risk and Return Analysis: DHR's annualized returns have been lower than Agilent Technologies (A) and Thermo Fisher Scientific (TMO) over the past three years. However, DHR's annualized volatility has also been lower than its peers, indicating that it is less risky. DHR's maximum drawdown of 36.59% is slightly lower than Agilent Technologies (A) at 42.73% and Thermo Fisher Scientific (TMO) at 35.07%, further supporting its lower risk profile.
  • Risk-Adjusted Performance: DHR's Sharpe Ratio has generally been lower than Agilent Technologies (A) and Thermo Fisher Scientific (TMO), suggesting that it may not be offering as good a risk-adjusted return as its peers. However, DHR's lower beta indicates that it is less sensitive to market movements, which could be considered a positive factor for investors seeking lower risk.
  • Overall Assessment: Danaher Corp. (DHR) presents a lower risk profile compared to its peers, Agilent Technologies, Inc. (A) and Thermo Fisher Scientific, Inc. (TMO), as evidenced by its lower volatility and maximum drawdown. However, DHR's lower annualized returns and Sharpe Ratio suggest that it may not be offering as good a risk-adjusted return as its peers. Investors seeking lower risk may find DHR attractive, while those seeking higher returns may prefer its peers. It is important to note that DHR's lower volatility and beta could be attributed to its diversified business model, which spans multiple segments within the healthcare industry. This diversification may provide some protection against market fluctuations.
Peers Fundamentals(as of 2024-06-30)
Thermo Fisher Scientific, Inc. (TMO)Agilent Technologies, Inc. (A)
  1. Market Position and Size:
    • DHR is a large-cap company within the "Health Technology" sector and "Medical Specialties" industry, with a market cap of 191018.0 million, significantly larger than Agilent Technologies, Inc. (A) but smaller than Thermo Fisher Scientific, Inc. (TMO).
    • DHR's market cap is not directly proportional to its earnings per share, suggesting that the market may be valuing other factors, such as growth potential and profitability.
  2. Profitability and Efficiency:
    • DHR exhibits strong profitability, with significantly higher Gross Profit Margin, EBITDA Margin, and Net Profit Margin compared to peers and the industry average.
    • However, DHR's efficiency in generating returns, as measured by ROA, ROE, ROTC, and ROIC, is lower than its peers, despite its strong profitability.
  3. Financial Health and Stability:
    • DHR maintains a strong financial position with a conservative approach to debt management, resulting in lower debt levels compared to peers and the industry average.
    • However, DHR's liquidity is lower than its peers and the industry average, suggesting a more conservative approach to managing its working capital.
  4. Valuation and Market Perception:
    • DHR's valuation metrics are mixed, with some suggesting a premium valuation compared to peers, while others suggest a discount compared to the industry average.
    • The market may be valuing DHR's growth potential and profitability, but also considering its lower efficiency and returns compared to its peers.
  5. Cash Flow and Capital Management:
    • DHR generates significant free cash flow, indicating its ability to fund future growth and return value to shareholders.
    • DHR's cash flow generation strength is strong, but lower than TMO, despite its larger market cap, suggesting a more conservative approach to capital allocation.
  6. Growth and Future Prospects:
    • DHR's growth metrics show a mixed picture, with strong growth in profitability metrics but slower growth in revenue and assets.
    • DHR's growth rates have been volatile, with significant year-to-year fluctuations, and a deceleration in growth over the past three years.
    • DHR's growth profile is characterized by strong profitability growth, but slower revenue and asset growth, suggesting challenges in expanding its market share.
  7. Potential for Investment:
    • DHR is an attractive investment for investors seeking a company with strong profitability and cash flow generation.
    • However, its lower efficiency in generating returns and slower growth in revenue and assets may be a concern for investors seeking high growth potential.
    • Investors should carefully consider DHR's growth potential and efficiency compared to its peers before making an investment decision.
  8. Key Risks and Considerations:
    • DHR's lower efficiency in generating returns and slower growth in revenue and assets may limit its ability to compete aggressively in a rapidly evolving industry.
    • DHR's conservative approach to debt management and capital allocation may also limit its ability to compete aggressively in a rapidly evolving industry.
  9. Overall Assessment:
    • DHR is a financially healthy company with strong profitability and cash flow generation.
    • However, its efficiency in generating returns is lower than its peers, and its growth in revenue and assets has been slower.
    • DHR's liquidity is also lower than its peers and the industry average.
    • Overall, DHR's financial health is strong, but its growth potential and efficiency may be limited compared to its peers.